Financial Performance - The company's revenue for Q3 2025 reached ¥914,425,451.81, an increase of 7.71% year-over-year[5] - Net profit attributable to shareholders was ¥36,898,552.85, representing a significant increase of 100.30% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥36,118,653.83, up 164.39% year-over-year[5] - Basic and diluted earnings per share were both ¥0.0347, reflecting a growth of 73.50% compared to the previous year[5] - The company experienced a 211.75% increase in net profit for the year-to-date period, totaling ¥101,439,584.84[10] - Total operating revenue for the current period reached ¥2,725,441,125.37, an increase of 4.84% compared to ¥2,599,501,682.23 in the previous period[19] - Operating profit for the current period was ¥127,584,120.21, significantly up from ¥38,468,475.93 in the previous period, marking an increase of 231.5%[20] - Net profit attributable to shareholders of the parent company was ¥101,439,584.84, compared to ¥32,539,075.11 in the previous period, reflecting a growth of 211.5%[20] - The total comprehensive income for the third quarter of 2025 was ¥151,824,798.90, an increase from ¥113,661,112.03 in the same period last year, representing a growth of approximately 33.5%[21] - Basic and diluted earnings per share increased to ¥0.0954 from ¥0.0306, marking a significant rise of 211.4% year-over-year[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥6,424,740,706.92, a 9.41% increase from the end of the previous year[5] - Total assets increased to ¥6,424,740,706.92 from ¥5,872,304,877.63, representing a growth of 9.39%[18] - Total liabilities decreased slightly to ¥2,744,965,892.71 from ¥2,772,603,646.68, a reduction of 1.0%[18] - The company's equity attributable to shareholders rose to ¥3,679,774,814.21 from ¥3,099,701,230.95, an increase of 18.7%[18] - The total non-current assets amounted to ¥4,103,246,601.18, slightly down from ¥4,171,895,461.69, a decline of 1.6%[18] Cash Flow - The company's cash flow from operating activities showed a net increase of ¥67,165,018.40, a remarkable rise of 585.10% year-over-year[10] - Net cash flow from operating activities was ¥67,165,018.40, compared to ¥9,803,728.77 in the previous year, indicating a substantial improvement[21] - Cash inflow from operating activities totaled ¥2,342,897,454.42, while cash outflow was ¥2,275,732,436.02, resulting in a net cash inflow from operations[21] - The company reported a net cash inflow from financing activities of ¥519,839,262.97, a significant turnaround from a net outflow of ¥11,280,171.95 in the previous year[10] - Total cash inflow from financing activities reached ¥1,856,474,370.55, up from ¥1,184,734,972.22, reflecting a growth of approximately 56.6%[22] - The cash and cash equivalents at the end of the period increased to ¥759,109,354.88 from ¥262,240,372.53, showing a significant rise of 189.5%[22] - The company reported a decrease in cash outflow for investment activities to ¥76,996,870.60 from ¥90,118,746.80, indicating improved cash management[22] Shareholder Information - The company issued 79,121,376 shares at a price of 5.52 CNY per share, raising a total of 436,749,995.52 CNY, with a net amount of 428,248,784.36 CNY after deducting issuance costs[15] - The total number of shares outstanding after the issuance is 1,142,821,917 shares[15] - The company has not disclosed any changes in the participation of major shareholders in margin trading[14] - There are no preferred shareholders or significant changes in the top 10 shareholders' participation in margin trading[14] Expenses and Impairments - Research and development expenses for the current period were ¥84,613,370.78, down from ¥94,138,259.64, indicating a decrease of 10.1%[19] - The company reported a credit impairment loss of ¥-3,531,860.83, worsening from ¥-735,890.48 in the previous period[20] - Other comprehensive income after tax for the current period was ¥50,385,214.06, compared to ¥81,122,036.92 in the previous period, a decrease of 38.0%[20] Future Outlook - The company is set to implement new accounting standards starting in 2025, which may impact future financial reporting[23] - The company did not report any audited financial statements for the third quarter of 2025[23]

Group 1 - The company Brother Technology (002562) announced a share reduction plan involving its chairman and several board members [1][2] - Chairman Qian Zhida plans to reduce his holdings by up to 11,428,219 shares, representing 1.00% of the total share capital [1][2] - Other board members, including Zhou Zhongping, Tang Yueqiang, and Qian Liuhua, also plan to reduce their holdings, with total reductions amounting to 13,102,800 shares and an estimated total value of 93.42 million yuan [2] Group 2 - As of October 28, 2025, Brother Technology's stock closed at 7.13 yuan per share, leading to estimated proceeds from the reductions of approximately 81.48 million yuan for Qian Zhida and smaller amounts for other board members [2] - The company disclosed that its controlling shareholders are Qian Zhida and Qian Zhiming, with familial relationships among the actual controllers [2] - Brother Technology previously completed a share reduction by Qian Zhida from April 28 to July 15, 2025, totaling 31,829,410 shares at a price range of 4.96 to 5.65 yuan per share, amounting to 170 million yuan [3]

股票代码：002562 股票简称：兄弟科技 公告编号：2025-072 兄弟科技股份有限公司 关于公司部分董事及高级管理人员拟减持股份的预披露公告 董事钱志达、唐月强，董事及高级管理人员周中平，高级管理人员钱柳华 保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、公司董事长钱志达先生持有公司股份225,566,028股（占公司总股本的19.74%），计划 自本公告披露之日起 15 个交易日后的3个月内，以集中竞价方式或大宗交易方式共计减持公 司股份不超过11,428,219股（占公司总股本的1.00%）。 2、公司董事、副总裁周中平先生持有公司股份3,376,000股（占公司总股本的0.30%），计 划自本公告披露之日起 15 个交易日后的3个月内，以集中竞价方式或大宗交易方式共计减持 公司股份不超过800,000股（占公司总股本的0.07%）。 3、公司董事唐月强先生持有公司股份2,698,240股（占公司总股本的0.24%），计划自本公 告披露之日起 15 个交易日后的3个月内，以集中竞 ...

Group 1 - The chairman of the company, Qian Zhida, plans to reduce his shareholding by up to approximately 11.43 million shares, which accounts for 1% of the total share capital, within three months after the announcement [1] - The company's vice president, Zhou Zhongping, intends to reduce his holdings by up to 800,000 shares, representing 0.07% of the total share capital, within the same timeframe [1] - Director Tang Yueqiang plans to sell up to 670,000 shares, which is 0.06% of the total share capital, also within three months after the announcement [1] - The company’s board secretary, Qian Liuhua, will reduce her holdings by up to 200,000 shares, accounting for 0.02% of the total share capital, within the specified period [1] Group 2 - For the first half of 2025, the company's revenue composition shows that fine chemicals account for 97.09% of total revenue, while other segments contribute 2.91% [2] Group 3 - The current market capitalization of the company is 8.1 billion yuan [3]

Core Points - The company held its 19th meeting of the 6th Board of Directors on October 27, 2025, where several resolutions were passed regarding the management and utilization of raised funds [2][3][5]. Group 1: Fund Management and Utilization - The company approved the establishment of a special account for raised funds and signed a tripartite/four-party supervision agreement for fund storage [3]. - The company decided to adjust the actual investment amount of raised funds for specific projects in 2023 [4]. - The company will use part of the idle raised funds for cash management, with a limit of up to 200 million yuan [38]. Group 2: Fund Allocation to Subsidiaries - The company approved the use of raised funds to increase capital or provide loans to its wholly-owned subsidiary, Jiangxi Brother Pharmaceutical Co., Ltd., for project implementation [10][11]. - The total amount allocated for this purpose is 42,824.88 million yuan, which includes net interest income and financial gains [11][12]. Group 3: Fund Replacement and Reimbursement - The company will replace pre-invested self-raised funds and paid issuance expenses with raised funds, totaling 222,647,327.66 yuan [20][21]. - The company will ensure that the replacement of funds does not affect the normal implementation of the investment projects [22][23]. Group 4: Project Timeline and Adjustments - The company announced a delay in the project timeline for the "Annual Production of 600 Tons of Iodinated Contrast Agent Construction Project" to September 2026 [56][57]. - This delay is due to the later-than-expected arrival of raised funds, which has slowed the investment progress [57].

Core Viewpoint - Brother Technology (SZ 002562) announced a board meeting held on October 27, 2025, to discuss the extension of fundraising project timelines [1] Group 1: Company Financials - For the first half of 2025, Brother Technology's revenue composition was 97.09% from fine chemicals and 2.91% from other sources [1] - The current market capitalization of Brother Technology is 8.3 billion yuan [1]

股票代码：002562 股票简称：兄弟科技 公告编号：2025-069 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意兄弟科技股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2025〕1174号）同意注册，本次向特定对象 发行人民币普通股79,121,376股（以下简称"本次发行"），每股面值人民币1.00元，每股发行 价格为人民币5.52元。本次发行募集资金总额为人民币436,749,995.52元，扣除本次发行费用 人民币8,501,211.16元（不含税）后，募集资金净额为人民币428,248,784.36元。上述募集资金 到位情况经天健会计师事务所（特殊普通合伙）验证，并由其出具了《验资报告》（天健验 [2025]298号）。公司对募集资金采取专户存储管理，并与保荐机构、募集资金专户所在银行 签订了募集资金三方/四方监管协议。 二、募集资金使用情况说明 公司于2025年10月27日召开第六届董事会第十九次会议，审议通过了《关于调整2023年 度向特定对象发行股票募投项目实际募集资金投入金额的议案》，调整后公司募集资金拟投入 1 情况如下： 单位：万元 兄弟科 ...

证券代码：002562 证券简称：兄弟科技 公告编号：2025-071 兄弟科技股份有限公司 关于使用募集资金置换预先投入募投项目及已支付发行费用 的自筹资金的公告 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意兄弟科技股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2025〕1174 号）同意注册，本次向特定对 象发行人民币普通股 79,121,376 股（以下简称"本次发行"），每股面值人民币 1.00 元，每股 发行价格为人民币 5.52 元。本次发行募集资金总额为人民币 436,749,995.52 元，扣除本次发 行费用人民币 8,501,211.16 元（不含税）后，募集资金净额为人民币 428,248,784.36 元。上述 募集资金已于 2025 年 9 月 29 日划至公司指定账户，募集资金到位情况经天健会计师事务所 （特殊普通合伙）验证，并由其出具了《验资报告》（天健验[2025]298 号）。公司对募集资金 采取专户存储管理，并与保荐机构、募集资金专户所在银行签订了募集资金三方/四方监管协 议。 二、募集资金投资项目情况 公司于2025年10月 ...

经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意兄弟科技股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2025〕1174号）同意注册，本次向特定对 象发行人民币普通股79,121,376股（以下简称"本次发行"），每股面值人民币1.00元，每股发 行价格为人民币5.52元。本次发行募集资金总额为人民币436,749,995.52元，扣除本次发行费 用人民币8,501,211.16元（不含税）后，募集资金净额为人民币428,248,784.36元。上述募集资 金到位情况经天健会计师事务所（特殊普通合伙）验证，并由其出具了《验资报告》（天健 验[2025]298号）。 二、募集资金专户的开立情况和《募集资金三方监管协议》、《募集资金四方监管协议》 的签订情况 为规范公司募集资金管理，保护投资者权益，根据《中华人民共和国证券法》《上市公 司募集资金监管规则》等有关法律法规及公司《募集资金管理制度》的规定，公司、本次募 投项目实施主体江西兄弟医药有限公司（以下简称"兄弟医药"）在中国民生银行股份有限公 司、中国农业银行股份有限公司、中国银行股份有限公司（以下合称"开户银行"）开设募集 资金专项账 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"公司"）于2025年10月27日召开第六届董事会第十九 次会议、第六届监事会第十四次会议，会议审议通过了《关于使用募集资金向全资子公司增 资、提供借款或增资与提供借款相结合的方式以实施募投项目的议案》，同意公司使用募集资 金42,824.88万元（含利息收入、理财收益扣除银行手续费的净额等，具体金额以实际结转时 募集资金专户余额为准）向公司全资子公司江西兄弟医药有限公司（以下简称"兄弟医药"） 增资、提供借款或增资与提供借款相结合的方式以实施募投项目。根据《深圳证券交易所股 票上市规则》《公司章程》等相关规定，本次不构成关联交易，不构成《上市公司重大资产重 组管理办法》规定的重大资产重组。该事项无需提交公司股东大会审议。现将具体情况公告 如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意兄弟科技股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2025〕1174号）同意注册，本次向特定对象 发行人民币普通股79,121,376股（以下简 ...